Esperion Therapeutics | ESPR - Current Assets


Esperion Therapeutics reported $462.57M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Alterity Therapeutics Limited AUD 37.91M 15.92M Dec/2025
Amarin USD 626.02M 23.87M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Cipla INR 249.18B 16.3B Sep/2025
CSL USD 11.85B 1000K Dec/2025
Cytokinetics USD 839.46M 77.51M Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
Geron USD 520.27M 2.07M Dec/2025
Grifols EUR 5.96B 316.31M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Moderna USD 5.77B 774M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
United Therapeutics USD 3.7B 208.5M Dec/2025
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025